Že nekaj časa poteka razprava v strokovni javnosti, ali naj nizka izraženost HER2 postane nova kategorija HER2, a zaenkrat trenutnega poročanja statusa HER2 patologi in onkologi ne bodo spremenili. Zakaj je HER2-low oziroma tumor z nizko izraženostjo HER2 tako pomemben in zakaj sodelovanje onkologa in patologa postaja še pomembnejše? Določanje HER2 in novosti v zdravljenju tumorjev z nizko izraženostjo HER2 pojasnjujeta specialistka internistične onkologije doc.dr. Erika Matos in specialistka anatomske patologije doc. dr. Gorana Gašljević.

Rak dojk z nizkim izražanjem HER2

Povezava do <a href="https://public.mediately.co/assets/wp-uploads/2023/12/28104702/CME-HER2Low-Matos.pdf">predstavitve</a>

Določanje statusa HER2 in novosti v zdravljenju tumorjev z nizko izraženostjo HER2 – Pogled patologa

Povezava do <a href="https://public.mediately.co/assets/wp-uploads/2023/12/28110902/CME-HER2Low-Gasljevic.pdf">predstavitve</a>

<ol>
<li>Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Salmon. Science. 1987;235:177. Ran. Onco Targets Ther. 2020;13:4385.</li>
<li>National Cancer Institute: Surveillance, Epidemiology and End Results programs: seer.cancer.gov/statfacts/html/breast-subtypes.html.</li>
<li>Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Marchiò. Semin Cancer Biol. 2021:72:123.</li>
<li>How I treat HER2-low advanced breast cancer. Schlam. The Breast. 2023.</li>
<li>NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+. SFehrenbacher, JCO. 2020;</li>
<li>Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Modi. JCO. 2020;38:1887., Modi. NEJM. 2022;387:9</li>
<li>Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Curigliano. Ann Oncol 2023.</li>
<li>ESMO ​Metastatic Breast Cancer Living Guideline (<a href="https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline">https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline</a>)</li>
<li>ESMO ​Metastatic Breast Cancer Living Guideline (<a href="https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline">https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline</a>)</li>
<li>Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test. Sajjadi et al: Front Mol Biosc 2023</li>
<li>Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Moutafi et al: Lab Invest 2022</li>
<li>Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcomes. Harigopal et al: Am J Pathol 2010</li>
<li>Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. Yardley et al: Breast Canc Res 2015</li>
<li>A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2. Jensen et al: Mod Pathol 2017</li>
<li>HER2-17 Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 IHC 0 “Ultra-Low” Setting: Implications for Precision Therapy in HER2- Breast Cancer. Petricoin at al: Cancer Res 2023</li>
<li>TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Bardia et al: Targ Oncol 2023</li>
<li>Selecting patients with HER2-low breast cancer: Getting out of the tangle. Baez Navarro et al: Eur J Canc 2022</li>
<li>Tan, Mihir, Laokulrath, Rakha: Histopathology 2023. doi: 10.111/his.15117: I-C-E</li>
</ol>

Avtor/ji

Opravite izobraževanje in pridobite kreditne točke

Rak dojk z nizkim izražanjem HER2

Določanje statusa HER2 in novosti v zdravljenju tumorjev z nizko izraženostjo HER2 – Pogled patologa

Reference

Uporabite Mediately aplikacijo

Uporabite Mediately aplikacijo